Astonea Labs IPO Opens For Subscription, Check Price Band, GMP & Key Dates
Mumbai: The IPO (Initial Public Offering) of Astonea Labs opened for public subscription today, May 27, 2025. The issue is worth around Rs 37.67 crore and includes a fresh issue of 27.9 lakh equity shares. This IPO is being launched on the SME platform, which is specially made for small and medium-sized companies.
Price Band and Lot Size
The price band for Astonea Labs IPO is set between Rs 128 and Rs 135 per share. The minimum investment for retail investors is one lot, which includes 1,000 shares. At the upper price of Rs 135, this means a total investment of Rs 1,35,000. High net-worth individuals (HNIs) need to apply for at least two lots, which means 2,000 shares and an investment of Rs 2,70,000.
GMP and Market Response
According to market sources, the grey market premium (GMP) for Astonea Labs is currently nil. The shares were trading at Rs 135 in the unofficial market, which is the same as the upper price band. This means there is no premium or discount in grey market trading as of May 28, 2025.
Important Dates
IPO Opens: May 27, 2025
IPO Closes: May 29, 2025
Allotment Date: May 30, 2025
Demat Credit: June 2, 2025
Listing Date: Expected shortly after credit
Purpose of the IPO
Astonea Labs plans to use the money raised through this IPO for several important business activities:
- Registering products in Bolivia, South America
- Buying and installing machines to make export-quality ointments
- Spending on marketing and brand building
- Buying software and hardware
- Meeting working capital needs
- For general business purposes
About the Company
Astonea Labs is a pharmaceutical and cosmetic company. It makes and sells many types of products, including:
- Medicines for cold, allergies, diabetes, and heart problems
- Products for women’s health, skin, hair, and dental care
- Gels, creams, lotions, oils, and serums
It also trades in raw materials and packaging items used in the healthcare industry.
Registrar: Kfin Technologies
Lead Manager: Oneview Corporate Advisors
news